Working… Menu

Evaluating the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Carbavance™ (RPX2014/RPX7009) in Healthy Adult Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02073812
Recruitment Status : Completed
First Posted : February 27, 2014
Last Update Posted : March 5, 2018
Information provided by (Responsible Party):
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)

Brief Summary:
RPX7009(beta-lactamase inhibitor) is being studied in combination with a carbapenem (RPX2014) to treat bacterial infections, including those due to multi-drug resistant bacteria.

Condition or disease Intervention/treatment Phase
Healthy Subjects Drug: RPX7009 and RPX2014 Phase 1

Detailed Description:

The worldwide spread of resistance to antibiotics among Gram-negative bacteria, particularly members of the ESKAPE group of pathogens, has resulted in a crisis in the treatment of hospital acquired infections. In particular, the recent dissemination of a serine carbapenemase (e.g., KPC) in Enterobacteriaceae in US hospitals now poses a considerable threat to the carbapenems and other members of the beta-lactam class of antimicrobial agents.

Rempex is developing a fixed combination antibiotic of a carbapenem (RPX2014) plus a new beta-lactamase inhibitor (RPX7009) which has activity against serine beta-lactamases, including KPC. This Phase 1 study will assess the pharmacokinetics of intravenous RPX2014 and RPX7009 in plasma and epithelial fluid.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 26 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Randomized, Open-Label, Trial Evaluating the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations of Intravenous Carbavance™ (RPX2014/RPX7009) in Healthy Adult Subjects
Study Start Date : February 2014
Actual Primary Completion Date : April 2014
Actual Study Completion Date : April 2014

Arm Intervention/treatment
Experimental: Multiple dose of Carbavance (RPX7009/RPX2014)
Multiple dose of Carbavance
Drug: RPX7009 and RPX2014
The study is designed to enroll approximately 25 healthy subjects. The study will evaluate the plasma, epithelial lining fluid, and alveolar macrophage concentrations of Carbavance (RPX7009/RPX2014)

Primary Outcome Measures :
  1. Pharmacokinetics from baseline through the end of the study [ Time Frame: 2 days ]
    Assessment of plasma, ELF and AM concentrations of RPX2014 and RPX7009 after 3 doses of Carbavance

Secondary Outcome Measures :
  1. IV Carbavance concentrations in lung fluid [ Time Frame: 2 days ]
    Plasma, ELF and AM concentrations of intravenous Carbavance in healthy adult subjects.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Healthy adult males and/or females, 18 to 55 years of age (inclusive) at the time of screening.
  2. Body mass index (BMI) ≥ 18.5 and ≤ 30 (kg/m2) and weight between 55.0 and 100.0 kg (inclusive) at the time of screening.
  3. Medically healthy with clinically insignificant screening results (e.g., laboratory profiles, medical histories, electrocardiograms (ECGs), physical examination) as deemed by the PI.
  4. Non-tobacco/nicotine-containing product users for a minimum of 6 months prior to Day 1.
  5. Voluntarily consent to participate in the study.

Exclusion Criteria:

  1. History or presence of significant oncologic, cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, neurological, or psychiatric disease.
  2. Positive urine drug/alcohol testing at screening (or Day -1).
  3. Positive testing for human immunodeficiency virus (HIV) or hepatitis B surface antigen (HBsAg).
  4. History or presence of alcoholism or drug abuse within the 2 years prior to Day 1.
  5. Hypersensitivity or idiosyncratic reaction to beta-lactam antibiotics (e.g. penicillins, cephalosporins, carbapenems, etc.).
  6. Clinically significant pulmonary or any other disease that prevents a subject from undergoing bronchoscopy with bronchopulmonary lavage.
  7. History of seizures (e.g., epilepsy), head injury or meningitis requiring ongoing anti-seizure medications.
  8. Use of any prescription medication (with the exception of hormonal contraceptives or hormone replacement therapy for females) within 14 days prior to Day 1.
  9. Participation in another investigational clinical trial within 30 days prior to Day 1.
  10. Females who are pregnant or lactating.
  11. Surgery within the past three months prior to Day 1 determined by the PI to be clinically relevant.
  12. Any acute illness including clinically significant infection within 30 days prior to Day 1.
  13. QTcF interval >450 msec, or history of prolonged QT syndrome at screening (or Day 1).
  14. Calculated creatinine clearance less than 80 mL/min (Cockroft-Gault method) at screening.
  15. Subjects who have any clinically significant abnormalities on laboratory values at screening (or Day -1), including:

    1. White blood cell count (WBC) < 3,000/mm3, hemoglobin < 11g/dL.
    2. Absolute neutrophil count < 1,200/mm3 or platelet count < 120,000/mm3.
  16. Liver function abnormalities at screening (or Day -1) (defined by an elevation in bilirubin, AST or ALT 1.5 x ULN of the normal range for subjects based on age and sex).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02073812

Layout table for location information
United States, Arizona
Pulmonary Associates
Phoenix, Arizona, United States, 85006
Sponsors and Collaborators
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
Layout table for investigator information
Principal Investigator: Mark Gotfried, MD Pulmonary Associates
Layout table for additonal information
Responsible Party: Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) Identifier: NCT02073812    
Other Study ID Numbers: Rempex 503
First Posted: February 27, 2014    Key Record Dates
Last Update Posted: March 5, 2018
Last Verified: March 2018